- Home
- OBIO vs ECF Comparison
OBIO vs ECF Comparison
Compare OBIO & ECF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ECF
- Stock Information
- Founded
- OBIO 2017
- ECF 1986
- Country
- OBIO United States
- ECF United States
- Employees
- OBIO N/A
- ECF N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ECF Finance/Investors Services
- Sector
- OBIO Health Care
- ECF Finance
- Exchange
- OBIO Nasdaq
- ECF Nasdaq
- Market Cap
- OBIO 156.6M
- ECF 132.9M
- IPO Year
- OBIO N/A
- ECF N/A
- Fundamental
- Price
- OBIO $5.28
- ECF $9.90
- Analyst Decision
- OBIO Strong Buy
- ECF
- Analyst Count
- OBIO 5
- ECF 0
- Target Price
- OBIO $15.80
- ECF N/A
- AVG Volume (30 Days)
- OBIO 182.8K
- ECF 57.7K
- Earning Date
- OBIO 11-12-2024
- ECF 01-01-0001
- Dividend Yield
- OBIO N/A
- ECF 6.42%
- EPS Growth
- OBIO N/A
- ECF N/A
- EPS
- OBIO N/A
- ECF 0.46
- Revenue
- OBIO $2,647,000.00
- ECF N/A
- Revenue This Year
- OBIO $22.61
- ECF N/A
- Revenue Next Year
- OBIO $16.64
- ECF N/A
- P/E Ratio
- OBIO N/A
- ECF $17.61
- Revenue Growth
- OBIO N/A
- ECF N/A
- 52 Week Low
- OBIO $3.96
- ECF $7.02
- 52 Week High
- OBIO $10.06
- ECF $8.91
- Technical
- Relative Strength Index (RSI)
- OBIO 50.69
- ECF 57.04
- Support Level
- OBIO $5.00
- ECF $9.51
- Resistance Level
- OBIO $5.70
- ECF $9.90
- Average True Range (ATR)
- OBIO 0.57
- ECF 0.14
- MACD
- OBIO 0.05
- ECF 0.00
- Stochastic Oscillator
- OBIO 56.41
- ECF 86.67
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ECF Ellsworth Growth and Income Fund Ltd.
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.